Rating Change
Guggenheim analysts reiterated a Buy rating on GeneDx Holdings Corp. (NASDAQ:WGS) on June 29, 2026.
reiterateNASDAQ:WGS
Guggenheim Reiterates Buy Rating on GeneDx Holdings Corp. (WGS)
Rating Change Guggenheim analysts reiterated a Buy rating on GeneDx Holdings Corp. (NASDAQ:WGS) on June 29, 2026. Market Context GeneDx Holdings Corp.
Market Context
GeneDx Holdings Corp. operates in the Healthcare sector. The stock currently trades at $69.12 with a market capitalization of $4.5B.
Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for GeneDx Holdings Corp..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for GeneDx Holdings Corp.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 29, 2026 | Guggenheim | Buy | N/A |
| Jun 23, 2026 | Piper Sandler | Overweight | N/A |
| May 05, 2026 | Canaccord Genuity | Buy | N/A |
| May 05, 2026 | Guggenheim | Buy | N/A |
| May 05, 2026 | Wells Fargo | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View WGS Stock Page
Frequently Asked Questions
What does a Buy rating mean for WGS?
A Buy rating from Guggenheim reflects the analyst's outlook on GeneDx Holdings Corp. (NASDAQ:WGS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the WGS forecast page.